Literature DB >> 19004543

Cathepsin B is a target of Hedgehog signaling in pancreatic cancer.

Jin-Hyeok Hwang1, Sang Hyub Lee, Kwang Hyuck Lee, Keung Youp Lee, Haeryoung Kim, Ji Kon Ryu, Yong Bum Yoon, Yong-Tae Kim.   

Abstract

This study investigated the influence of cathepsin B (CATB), a downstream target of Hedgehog (Hh) signaling, in pancreatic cancer. Cyclopamine (Hh signal inhibitor) suppressed expression of Shh, as well as Hh-induced transcription factor Gli1, and induced apoptosis in Shh-positive pancreatic cancer cell line (PANC-1). Microarray analysis revealed CATB as a gene downregulated by Hh. Cyclopamine reduced CATB protein and mRNA levels. Cyclopamine or CATB inhibitor reduced PANC-1 cell invasiveness (P<0.05). CATB expression in human pancreatic cancer tissues tended to correlate with Shh expression (P=0.053). Conclusively, Hh targets CATB and Hh signaling through CATB might influence pancreatic cancer cell invasiveness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004543     DOI: 10.1016/j.canlet.2008.08.028

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

1.  Ski modulate the characteristics of pancreatic cancer stem cells via regulating sonic hedgehog signaling pathway.

Authors:  Libin Song; Xiangyuan Chen; Song Gao; Chenyue Zhang; Chao Qu; Peng Wang; Luming Liu
Journal:  Tumour Biol       Date:  2016-10-12

2.  Refactored M13 bacteriophage as a platform for tumor cell imaging and drug delivery.

Authors:  Debadyuti Ghosh; Aditya G Kohli; Felix Moser; Drew Endy; Angela M Belcher
Journal:  ACS Synth Biol       Date:  2012-09-24       Impact factor: 5.110

3.  Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.

Authors:  A K Nalla; B Gorantla; C S Gondi; S S Lakka; J S Rao
Journal:  Cancer Gene Ther       Date:  2010-05-07       Impact factor: 5.987

4.  Cathepsin B is the driving force of esophageal cell invasion in a fibroblast-dependent manner.

Authors:  Claudia D Andl; Kelsey M McCowan; Gillian L Allison; Anil K Rustgi
Journal:  Neoplasia       Date:  2010-06       Impact factor: 5.715

5.  Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.

Authors:  Majid Momeny; Zivar Alishahi; Haniyeh Eyvani; Fatemeh Esmaeili; Azam Zaghal; Parisa Ghaffari; Javad Tavakkoly-Bazzaz; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Journal:  Cell Oncol (Dordr)       Date:  2019-09-06       Impact factor: 6.730

6.  The molecular targets for the diagnosis and treatment of pancreatic cancer.

Authors:  Alexios S Strimpakos; Kostas N Syrigos; Muhammad Wasif Saif
Journal:  Gut Liver       Date:  2010-12-17       Impact factor: 4.519

7.  Active sonic hedgehog signaling between androgen independent human prostate cancer cells and normal/benign but not cancer-associated prostate stromal cells.

Authors:  Katsumi Shigemura; Wen-Chin Huang; Xiangyan Li; Haiyen E Zhau; Guodong Zhu; Akinobu Gotoh; Masato Fujisawa; Jingwu Xie; Fray F Marshall; Leland W K Chung
Journal:  Prostate       Date:  2011-04-25       Impact factor: 4.104

8.  Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion.

Authors:  Wan-Nan Chen; Jin-Yan Chen; Bo-Yan Jiao; Wan-Song Lin; Yun-Li Wu; Ling-Ling Liu; Xu Lin
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

9.  Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms.

Authors:  Brahma N Singh; Junsheng Fu; Rakesh K Srivastava; Sharmila Shankar
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

10.  Cathepsin B as a potential prognostic and therapeutic marker for human lung squamous cell carcinoma.

Authors:  Fengming Gong; Xingchen Peng; Can Luo; Guobo Shen; Chengjian Zhao; Liqun Zou; Longhao Li; Yaxiong Sang; Yuwei Zhao; Xia Zhao
Journal:  Mol Cancer       Date:  2013-10-20       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.